drugset / Trial / NCT00697918

Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

NCT00697918

Phase 3 Completed 11 enrolled SK Life Science, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of RWJ-333369 at doses between 200-800 mg/day in Korean and Japanese patients who have completed the preceding study (333369-KJ-02).

Timeline

Start
2008-03
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 100 mg Oral
Subject Carisbamate Small molecule 400 mg Oral

Indications